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Abstract 
Introduction: Ventilator-associated pneumonia (VAP) caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) is common in 
hospitals and impacts patient survival. We determined the incidence of MDR-AB VAP in critical care units and examined the predictors of 
14-day mortality in these patients. 
Methodology: A retrospective case series study was conducted at a tertiary referral teaching hospital in north Jordan. A list of patients with a 
positive culture of A. baumannii between January 2007 and June 2013 was retrieved using computerized hospital databases. Medical records 
of all these patients were reviewed, and cases of VAP infected with MDR-AB were identified. Predictors of 14-day mortality were 
determined using multivariable logistic regression adjusted for possible confounders. 
Results: Out of 121 A. baumannii-VAP cases, 119 (98.3%) were caused by MDR-AB. The incidence rate of MDR-AB VAP was 1.59 cases 
per 100 critical care unit admissions. The mortality of A. baumannii-VAP cases in critical care units was 42% (50/119). Being prescribed two 
or more definitive antibiotics (prescribed based on susceptibility data) (OR = 0.075, 95% CI = 0.017–0.340, p = 0.001) and 
ipratropium/salbutamol during mechanical ventilation (OR = 0.140, 95% CI = 0.028–0.705, p = 0.017) were independently associated with 
lower hospital mortality. 
Conclusions: Our results suggest incidence of MDR-AB VAP in critical care units is high and that prescription of antibiotics based on 
antibiotic susceptibility and use of bronchodilators is associated with lower mortality in this population. Larger prospective studies are 
needed to explore whether these findings can be replicated in different clinical settings. 
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Introduction 
Patients who are admitted to critical care units 
(CCUs) (intensive care unit [ICU], coronary care unit, 
cardiac ICU, and general intermediate care unit) are 
highly predisposed to nosocomial infections [1]. 
Ventilator-associated pneumonia (VAP) is considered 
one of the most common infections in these units [2]. 
The estimated incidence of VAP varies among 
different countries, ranging from 3% to 47% [3,4], 
with a mortality of 16% to 70% [3,5,6]. Acinetobacter 
baumannii, a Gram-negative coccobacillus, is 
increasingly becoming one of the most common 
pathogens causing VAP [2,5]. It is responsible for 
about 5% to 10% of VAP cases occurring in the ICU
 
[7]
 
and is associated with high ICU mortality (61%) 
[5].  
Worldwide, multidrug-resistant A. baumannii 
(MDR-AB) isolates are emerging [8,9] (i.e., A. 
baumannii isolates non-susceptible to at least one 
agent in three or more antimicrobial categories [8]). 
Published data suggest that mortality associated with 
MDR-AB infections ranges from 14.3% to 49% [9-
11], leading to significantly extended ICU and overall 
hospital stays as well as high healthcare costs [12-14]. 
Young et al. found that patients infected with MDR-
AB had a mean of US $60,913 additional charges and 
13 extra days of hospital stay [12]. It has been reported 
that VAP caused by A. baumannii or infection by 
another MDR pathogen was significantly associated 
with hospital mortality [2]. Prior studies have 
examined the predictors of mortality in patients with 
MDR-AB infections [11,15]. Bacteremia, 
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inappropriate use of antibiotics, age, co-morbidities, 
number of intravascular lines, number of days of 
ventilation, and severity of illness have all been 
identified as determinants of mortality in MDR-AB 
patients [11,15]. However, the association between 
these factors and mortality in patients with MDR VAP 
has not been determined. The study aimed to 
investigate the incidence of MDR-AB VAP in CCUs 
and the predictors of 14-day mortality in these 
patients. A secondary objective was to assess the 
patterns of antibiotic susceptibility of A. baumannii 
isolates. 
 
Methodology 
Study setting 
This retrospective case series study was conducted 
at King Abdullah University Hospital, a 497-bed 
tertiary referral teaching hospital in north Jordan with 
an annual average admission rate of 34,291 patients. 
The study was approved by the ethics committee in 
Jordan University of Science and Technology 
(2/64/2013). 
 
Case selection 
Cases were identified using computerized hospital 
databases. Patients who were ≥ 16 years of age, 
admitted to a CCU, and diagnosed with VAP caused 
mainly by A. baumannii isolates from bronchial wash, 
sputum, and pleural fluid between 1 January 2007 and 
30 June 2013 were included. Pneumonia was 
considered VAP if the onset occurred ≥ 48 hours after 
intubation and was diagnosed based on new or 
progressive pulmonary infiltrates on chest X-ray and 
two or more of the following: fever > 38°C or 
hypothermia < 35.5°C, leukocytosis > 12,000 cells/mL 
or leukopenia < 4,000 cells/mL, purulent bronchial 
secretions; and supported by the result of a qualitative 
culture test (positive for A. baumannii isolate) [16].
 
For patients who developed more than one isolate 
of A. baumannii, only the first isolate was considered. 
Patients with polymicrobial infections or with VAP 
caused by another microorganism before A. baumannii 
during the same hospital stay were excluded from the 
study. MDR-AB was defined as A. baumannii isolate 
non-susceptible to at least one agent in three or more 
antimicrobial categories [8]. Cases infected with 
MDR-AB VAP were divided, based on their clinical 
outcome on day 14 from the onset of VAP symptoms, 
into two groups. Cases who survived on day 14 were 
classified as the survival group, and cases who did not 
survive to day 14 of the onset of VAP were classified 
as the non-survival group. Ventilator care bundle for 
prevention of VAP [17,18] was adopted in the hospital 
institution in 2007; interventions include 1) no 
ventilatory circuit change unless specifically indicated; 
2) strict use of hand hygiene with alcohol; 3) use of 
appropriate educated and trained staff; 4) daily 
assessment of sedation medication; 5) oral care with 
chlorhexidine; 6) appropriate cuff pressure check at 
least every 24 hours; and 7) head of bed elevation of 
30 degrees. 
 
Data collection 
The required information for each patient was 
obtained by reviewing patients' files (initial admission 
assessment, critical care progress notes, medications 
sheet, nursing notes, and physicians’ orders) and 
computerized laboratory results. In vitro susceptibility 
of A. baumannii isolates was identified by the 
microbiology laboratory in the hospital. The following 
demographic and clinical data were collected and 
evaluated as possible predictors of hospital mortality: 
gender, age, body mass index, co-morbidities, 
previous hospitalization (admission to hospital within 
90 days prior to the present hospital admission) [19], 
recent invasive procedure (a procedure performed 
within the 48 hours preceding the positive culture of 
MDR-AB) [19], acute physiology and chronic health 
evaluation II (APACHE II) score at CCU admission 
day (higher score indicates poorer health functioning), 
primary CCU admission diagnosis, Glasgow coma 
scale at VAP day (coma was defined as Glasgow coma 
scale less than 9) [20], prior antibiotics used (receiving 
an antibiotic for at least 48 hours during the hospital or 
CCU stay) [4], length of stay in hospital before VAP, 
length of stay in CCUs before VAP, duration of 
mechanical ventilation (MV) before VAP, drug use 
during MV, and empirical antibiotic use (antibiotic 
that is given before the causative agent is identified) 
and definitive antibiotic use (antibiotic that is given 
when  the causative pathogen is known and based on 
susceptibility data) treatments received after VAP. 
 
Microbiology identification 
Identification of A. baumannii isolates and 
antibiotic susceptibility were performed (manually and 
automatically) in the hospital microbiology 
laboratories according to the Clinical and Lab 
Standards Institutes (CLSI) guidelines [21]. The type 
of isolate was identified manually using IMViC tests 
(indole test, methyl red test, Voges-Proskauer test, and 
citrate test), and the Kirby-Bauer disk diffusion 
method was utilized to determine the sensitivity of the 
identified isolate to tested antibiotics. Both the 
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identification and susceptibility testing were done 
automatically using the VITEK2 compact microscan 
system. 
 
Statistical analysis 
Continuous variables were presented as mean ± 
standard deviation, while categorical variables were 
presented as numbers and percentages. The incidence 
rate of MDR-AB VAP was calculated by dividing the 
total number of MDR-AB VAP cases by the number 
of CCU admissions and multiplying that number by 
100. The predictors of 14-day mortality were 
examined using the T test or Mann-Whitney 
(continuous variables) and Chi-square (χ2) test or 
Fisher’s exact test (categorical variables) as 
appropriate. In order to determine factors that were 
independently associated with mortality, logistic 
regression (LR) analysis was performed using the 
enter method. All variables with p ≤ 0.05 on univariate 
analysis were included in the logistic regression 
model. Odds ratio (OR) values and their 95% 
confidence intervals (95% CI) were calculated. All 
tests were two-sided, and statistical significance was 
set at p ≤ 0.05. All analysis was carried out using the 
Statistical Package for Social Sciences (SPSS) version 
20. 
 
Results 
During the study period, a total of 208 cases with 
positive culture of A. baumannii were identified. 
Eighty-seven cases were excluded because they did 
not meet VAP criteria (66.6%; 58/87), were pre-
infected by another pathogen (9.2%; 8/87), had 
inadequate data availability (9.2%; 8/87), or for other 
reasons (15%; 13/87), leaving 121 cases that met the 
study inclusion criteria. Of the 121 cases diagnosed 
with A. baumannii-VAP, 119 (98.3%) were caused by 
MDR-AB. Most cases were patients admitted to the 
ICU (78%; 93/119), followed by coronary care unit 
(10%; 12/119), cardiac ICU (6%; 7/119), and general 
intermediate care unit (6%; 7/119). In the current 
study, the overall incidence rate of MDR-AB VAP 
was 1.59 cases per 100 CCU admissions. 
Table 1 outlines detailed demographic and clinical 
characteristics of all cases enrolled in the study. More 
than half of included patients (63.9%) had at least one 
co-morbid disease. All patients received at least two 
drugs while they were receiving MV; the average 
number of drugs used was 6.6 ± 2.22 (range 2–13). 
Empirical therapy was used in all patients (100%), 
while definitive therapy was administered in 64.7% of 
patients (77/119). Fluoroquinolones were the most 
commonly used empirical agents (59.7%; 71/119), and 
colistin (64.9%; 50/ 77) was the most commonly used 
definitive antibiotic. 
Table 1. Demographic and clinical characteristics of patients. 
Variablea (n = 119) Count 
Gender   
Male 64 (53.8%) 
Female 55 (46.2%) 
Age at admission (years)b 55.5 ± 21.01 (17–96) 
Body mass indexb,c 28.0 ± 6.79 (16.7–57.2) 
Current smoker 23 (19.3%) 
Drug allergy  5 (4.2%) 
Presence of co-morbidities 76 (63.9%) 
 Hypertension 55 (46.2%) 
 Diabetes mellitus 39 (32.8%) 
 Coronary artery diseases 22 (18.5%) 
Number of co-morbiditiesb 1.3 ± 1.26 (0–4) 
Drugs used during MV 119 (100%) 
Number of drugs used during MVb 6.6 ± 2.22 (2–13) 
APACHE II score on unit admissionb,d 18.9 ± 9.12 (0–43) 
Recent invasive procedure  114 (95.8%) 
Number of recent invasive devicesb 1.8 ± 0.76 (0–4) 
Previous hospitalization 38 (31.9%) 
Patients transferred from other hospital 32 (26.9%) 
Glasgow coma scale < 9 at VAP day 90 (76.9%) 
APACHE: acute physiology and chronic health evaluation; MV: mechanical ventilation; VAP: ventilator-associated pneumonia; a All data expressed as n (%) 
of patients unless otherwise indicated; b Data described as mean ± standard deviation (SD); (range);c Data described for 98 cases (missing for 21 cases); d 
Data described for 103 cases (missing for 16 cases) . 
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  Table 2. Univariate analysis of 14-day mortality in MDR-AB VAP. 
Characteristicsa Survival (n = 69) Non-survival (n = 50) P value 
Male 40 (58%) 24 (48%) 0.282 
Age (years)b 54.7 ± 22.69 56.7 ± 18.59 0.589 
Body mass indexb,c  26.7 ± 6.68 29.9 ± 6.58 0.023 
Co-morbidities 43 (56.6%) 33 (43.4%) 0.680 
Previous hospitalization  21 (30.4%) 17 (34%) 0.681 
Number of recent invasive devicesb 1.7 ± 0.73 1.8 ± 0.80 0.475 
APACHE II score on unit admissionb,d 17.3 ± 8.01 21.1 ± 10.17 0.045 
Primary unit admission diagnosis   0.07 
Neurosurgical 27 (39.1%) 11 (22%)  
Surgical 8 (11.6%) 12 (24%)  
Medical 34 (49.3%) 27 (54%)  
Glasgow coma scale < 9 at VAP day 51 (76.1%) 39 (78%) 0.057 
Prior antibiotic use 61 (88.4%) 43 (86%) 0.696 
Hospital length of stay before VAP (days)b 8.1 ± 7.92 10.4 ± 9.62 0.194 
Unit length of stay before VAP (days)b 6.7 ± 5.96 8.2 ± 7.79 0.229 
MV duration before VAP (days)b 5.4 ± 4.55 5.6 ± 4.74 0.786 
Drugs used during MV    
Sedative agent 65 (94.2%) 46 (92%) 0.636 
Analgesic 32 (46.4%) 18 (36%) 0.258 
H2-blockers or proton pump inhibitors  66 (95.7%) 50 (100%) 0.135 
Vasopressor 30 (43.5%) 32 (64%) 0.027 
Ipratropium/salbutamol nebulizer 23 (33.3%) 7 (14%) 0.017 
Aspirin 5 (7.2%) 11 (22%) 0.020 
Number of drugs used during  MVb 6.4 ± 2.10 7.2 ± 2.30 0.032 
Number of empirical antibioticsb   0.371 
1 antibiotic 12 (17.4%) 6 (12%)  
2 antibiotics 22 (31.9%) 22 (44%)  
≥ 3 antibiotics 35 (50.7%) 22 (44%)  
Number of definitive antibioticsb   
     < 0.001 
None 14 (20.3%) 26 (52%) 
 1 antibiotic 11 (15.9%) 11 (22%) 
≥ 2 antibiotics 44 (73.8%) 13 (26%) 
APACHE: acute physiology and chronic health evaluation; MV: mechanical ventilation; VAP: ventilator-associated pneumonia; a All data expressed as n (%) 
of patients unless otherwise indicated; b Data described as mean ± standard deviation (SD); c Data described for 98 cases (missing for 21 cases); d Data 
described for 103 cases (missing for 16 cases). 
 
 
 
 
Table 3. Multivariable analysis of factors predicting 14-day mortality. 
Factors OR 95% CI P value 
Body mass indexa 1.048 0.958–1.146 0.308 
APACHE II score on unit admissionb 1.029 0.956–1.107 0.446 
Vasopressor during MV 2.324 0.618–8.743 0.212 
Ipratropium/salbutamol nebulizer during MV  0.140 0.028–0.705 0.017 
Aspirin during MV 3.398 0.534–21.609 0.195 
Number of drugs used during  MV 1.234 0.919–1.657 0.162 
Number of definitive treatments    
None Ref.   
1 antibiotic 0.393 0.084–1.834 0.235 
≥ 2 antibiotics 0.075 0.017–0.340 0.001 
CI: confidence interval; MV: mechanical ventilation; OR: odds ratio; a Data described for 98 cases (missing for 21 cases); b Data described for 103 cases 
(missing for 16 cases). 
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The 14-day mortality among patients infected with 
MDR-AB VAP was 42.0% (50/119). The results of the 
univariate analysis of predictors of mortality are 
shown in Table 2. There were significant differences 
between 14-day mortality and body mass index (p = 
0.023) and APACHE II score at CCU admission (p = 
0.045), with higher body mass index and APACHE II 
score in the non-survival group compared to the 
survival group. More cases in the non-survival group 
used aspirin and vasopressors and more drugs while on 
MV (p = 0.020, p = 0.027, and p = 0.032, 
respectively). In contrast, more cases in the survival 
group had used an ipratropium/salbutamol nebulizer 
during MV (p = 0.017) compared to the non-survival 
group. There was a significant difference in the use of 
definitive antibiotics between the survival and non-
survival groups (p < 0.001); the survival group used a 
higher number of definitive antibiotics compared to 
the non-survival group. 
Using multivariate logistic regression analysis 
adjusted for possible confounders (age and gender 
variables) (Table 3), being prescribed two or more 
definitive antibiotics (OR = 0.075, 95% CI = 0.017–
0.340, p = 0.001) and ipratropium/salbutamol (OR = 
0.140, 95% CI = 0.028–0.705, p = 0.017) were 
independently associated with lower mortality. 
Table 4 shows the results of antibiotic 
susceptibility assay for MDR-AB isolates. The strains 
were tested against different types of antibiotics. They 
had variable resistance to different antibiotics. No 
strain was sensitive to ceftriaxone, ciprofloxacin, 
pefloxacin, and ticarcillin/clavulanic acid, and only 
0.9% of isolated strains were susceptible to imipenem. 
Colistin was the most active agent (100% sensitive) 
followed by tigecycline (50%). 
 
Discussion 
To the best of our knowledge, this is the first 
retrospective study to provide detailed epidemiologic 
data and to evaluate predictive factors of mortality 
among patients with VAP infected with MDR-AB. 
The results of our study reveal three main findings. 
First, the percentage of MDR-AB in our study was 
98.3% of all VAP cases, which is higher than 
previously reported in VAP (20%–80.5%) [12,22,23] 
and other nosocomial infections (15.7%–75%) [10,24-
26] in different countries. Second, independent 
predictors of 14-day mortality in MDR-AB VAP 
patients were an inadequate number of definitive 
therapies and not using nebulized 
Table 4. Susceptibility assay of multidrug-resistant A. baumannii isolates. 
Percentage of  isolatesa 
Antibiotic 
Resistant Intermediate Sensitive 
77.0 6.6 16.4 Amikacin 
100 0.0 0.0 Ampicillin 
84.6 7.7 7.7 Ampicillin/sulbactam 
98.2 1.8 0.0 Aztreonam 
99.1 0.9 0.0 Cefepime 
99.1 0.9 0.0 Ceftazidime 
100 0.0 0.0 Ceftriaxone 
100 0.0 0.0 Ciprofloxacin 
0.0 0.0 100 Colistin 
92.0 5.3 2.7 Gentamicin 
97.4 1.7 0.9 Imipenem 
100 0.0 0.0 Levofloxacin 
98.2 0.0 1.8 Meropenem 
54.0 28.4 17.7 Minocycline 
100 0.0 0.0 Pefloxacin 
99.1 0.0 0.9 Piperacillin 
97.3 1.8 0.9 Piperacillin/Tazobactam 
11.6 63.8 24.6 Rifampin 
92.3 5.1 2.6 Tetracycline 
98.5 0.0 1.5 Ticarcillin 
100 0.0 0.0 Ticarcillin/clavulanic acid 
37.5 12.5 50.0 Tigecycline 
68.2 2.7 29.1 Tobramycin 
74.8 0.0 25.2 Co-trimoxazole 
a Percentage was considered as the tested antibiotics were different in different years. 
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ipratropium/salbutamol. Third, all VAP cases were 
susceptible to colistin in our institution. 
Consistent with previous studies [11], an 
inadequate number of definitive treatments was 
identified as one of the independent factors associated 
with higher mortality in the present study. This finding 
supports the use of antibiotics to which bacteria are 
susceptible and supports the prescription of two or 
more of those antibiotics rather than empirical 
prescription. The use of two or more antibiotics has 
the potential to broaden the antibiotic spectrum, to 
exert additive or synergistic effects, and to reduce the 
possible emergence of resistant bacteria or 
superinfection. However, drug availability, adverse 
drug reactions, drug-drug interactions, and cost are 
also important factors that should be considered in 
drug selection [27]. 
Those patients who were prescribed 
ipratropium/salbutamol nebulizer treatment had lower 
mortality. This is a combined product of ipratropium 
bromide and salbutamol sulfate that acts on both 
muscarinic and beta2-adrenergic receptors, 
respectively, in the lungs, leading to bronchodilation. 
Most patients on MV have respiratory failure, and this 
nebulizer improves air flow, relieves underlying 
inflammatory bronchospasm, and thus achieves better 
airway protection [28], which potentially could 
explain this association. Generally, this medication is 
used as supportive rather than curative therapy during 
MV to facilitate patient management [28]. More 
clinical studies are needed to explore the association 
between using a bronchodilator as adjunctive therapy 
and prognosis in MDR-AB infected cases. 
In our VAP cases, the resistance rate for colistin in 
susceptibility assays was zero, and it was the most 
commonly used definitive treatment of choice. 
Colistin is an old drug that was infrequently used due 
to its nephrotoxicity and neurotoxicity. More recently, 
it has been revived as one of the last-resort therapies 
for MDR-AB infections [7,9,23]. In our institution, 
colistin cannot be used as empirical therapy due to 
inadequate evidence in the literature supporting its 
usage [29], and sometimes, it is not available for 
definitive therapy. A multicenter, randomized clinical 
trial in Europe that it is designed to investigate the 
efficacy and safety of colistin as empirical therapy in 
treating VAP due to Gram-negative bacilli is currently 
ongoing [30]. Meanwhile, empirical use of colistin 
(based on infectious disease consultation) may be 
justified in some institutions by high incidence rates of 
resistant pathogens [31,32]. Future studies to explore 
the association between using colistin as empirical 
treatment and prognosis in MDR-AB infected cases 
are needed. 
Fluoroquinolones were the initial agents used most 
commonly in all VAP cases in our center, yet all A. 
baumannii isolates were resistant to fluoroquinolones. 
Current guidelines of the American Thoracic Society 
(ATS) and the Infectious Diseases Society of America 
(IDSA) for the management of VAP stress the clinical 
benefit of appropriate empirical therapy, which is 
defined as using initial antibiotics with in vitro activity 
against identified microorganisms causing infection 
[1]. Inadequate empirical therapy was reported to be 
associated with poor prognosis in patients with A. 
baumannii infection [11]. More targeted antibiotic 
therapy has the potential to improve clinical outcomes 
in patients with VAP [16].  
This study had some limitations. First, it was 
retrospective and completed in a single tertiary care 
hospital setting. Second, it is unclear if mortality in 
this study was influenced by the patient’s underlying 
condition rather than the actual mortality associated 
with MDR-AB VAP. Third, limited numbers of 
patients in each comparable group had the potential to 
restrict the ability to detect differences in the outcome 
of interest, leading to wide confidence intervals. 
Finally, we were unable to extract data on antibiotic 
dose or duration for any cases due to poor reporting. 
Therefore, the impact of antibiotic dose and duration 
on 14-day mortality is not known. Also, the effect of 
delay in starting antibiotic treatment is another factor 
to consider. This study was a preliminary and the 
findings exploratory. However, it is the largest study 
to provide detailed epidemiological data in this group 
of VAP patients with MDR-AB to date. 
 
Conclusions 
This study is unique in evaluating the predictors of 
mortality in monomicrobial VAP cases with MDR-
AB. Our results suggest the incidence of MDR-AB 
VAP in critical care units is high and that prescription 
of antibiotics based on antibiotic susceptibility rather 
than empirical prescription and the use of 
bronchodilators is associated with lower mortality in 
this population All MDR-AB VAP cases were 
susceptible to colistin, illustrating its potential as a 
first-line treatment for this condition. Larger 
prospective studies are needed to explore whether 
these findings can be replicated in different clinical 
settings. 
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